摘要
最近的研究揭示在复杂的致病过程的基础上,与系统性硬化症的进展(SSC)可管理的疾病仍然是个问题,治疗是无效的。更好地了解潜在的病理学能研究新的治疗方法,治疗风湿病越来越趋向于疾病/器官特异靶向性、独特的生物网络和信号转导通路。病理生理和临床SSC的多态性,表现为非选择性免疫抑制剂和新型高选择性药物的评价进行大型对照研究的一个主要障碍。生物靶向治疗策略的炎症或纤维化细胞因子和淋巴细胞的活化被证明在其他全身性风湿性疾病是有效的但有矛盾的结果在SSC。肿瘤坏死因子-α和白细胞介素-6阻断可改善硬皮病相关的关节炎,而消耗的B细胞可能对皮肤和肺纤维化的好处,但需要随机研究。本文批判性地评估现有的数据治疗硬皮病的免疫和抗纤维化策略重点。在肝纤维化过程中的衰减是未被满足的目标但要防止通过促进组织修复已在临床前研究表明潜在损害。这些研究结果为临床实践翻译希望建立新的治疗方案,改善患者的预后。
关键词: 系统性硬化,纤维化,生物治疗,利妥昔单抗,托珠单抗。
Current Medicinal Chemistry
Title:Molecular and Cellular Pathways as Treatment Targets for Biologic Therapies in Systemic Sclerosis
Volume: 22 Issue: 16
Author(s): Theodoros Dimitroulas, Dimitrios Daoussis, Alexandros Garyfallos, Petros P. Sfikakis and George D. Kitas
Affiliation:
关键词: 系统性硬化,纤维化,生物治疗,利妥昔单抗,托珠单抗。
摘要: Recent advances have shed light on the complex pathogenic processes that underlie the development and progression of Systemic Sclerosis (SSc) but management of the disease remains problematic and curative treatment is not available. Better understanding of the underlying pathology has enabled novel therapeutic approaches to be investigated, as therapies in rheumatology are becoming increasingly disease/ organ-specific, targeting unique biological networks and signalling pathways. The pathophysiologic and clinical pleiomorphism of SSc however, represents a major barrier to conducting large well-controlled studies for the evaluation of non-selective immunosuppressive and novel highly selective agents. Therapeutic biologic strategies targeting inflammatory or profibrotic cytokines and lymphocyte activation proved to be efficacious in other systemic rheumatic diseases but have demonstrated contradictory results in SSc. Blocking of tumour necrosis factor alpha and interleukin-6 may improve SSc-associated arthritis, while depletion of B-cells may have benefits for skin and lung fibrosis, but randomized studies are needed. In this review we critically appraise available data for the treatment of SSc focusing on immunologic and antifibrotic strategies. Attenuation of the fibrotic process remains an unmet goal but the potential to prevent damage by promoting tissue repair has been shown in preclinical studies. Translation of these findings into clinical practice will hopefully establish new therapeutic options and improve prognosis of these patients, for which our therapeutic armamentarium remains poor.
Export Options
About this article
Cite this article as:
Theodoros Dimitroulas, Dimitrios Daoussis, Alexandros Garyfallos, Petros P. Sfikakis and George D. Kitas , Molecular and Cellular Pathways as Treatment Targets for Biologic Therapies in Systemic Sclerosis, Current Medicinal Chemistry 2015; 22 (16) . https://dx.doi.org/10.2174/0929867322666150209161224
DOI https://dx.doi.org/10.2174/0929867322666150209161224 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Liposomal Drugs in the Treatment of Rheumatoid Arthritis
Current Rheumatology Reviews Cytotoxic T Lymphocyte Antigen 4 Gene +49 A/G (rs231775) Polymorphism and Susceptibility to Systemic Lupus Erythematosus
Current Rheumatology Reviews Traditional and Alternative Therapies for Refractory Angina
Current Pharmaceutical Design Forceps: Still an Option?
Current Women`s Health Reviews Late Sodium Current Inhibition: The Most Promising Antiarrhythmic Principle in the Near Future?
Current Medicinal Chemistry Perioperative Considerations in Rheumatoid Arthritis Patients
Current Rheumatology Reviews Epigenetic Multiple Modulators
Current Topics in Medicinal Chemistry Novel Colchicine Derivatives and their Anti-cancer Activity
Current Topics in Medicinal Chemistry Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Thematic Issue: Focal Atrial Tachycardias and Atrial Flutter: Are they Hot Enough to Make a Thematic Issue?)
Current Cardiology Reviews Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews Surgical Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Current Pharmaceutical Design What Does a Pediatrician Need to Know About Chronic Diarrhea?
Current Pediatric Reviews In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens
Current Pharmaceutical Design Bactericidal Activity of a Cationic Peptide on Neisseria meningitidis
Infectious Disorders - Drug Targets Cardiac Biomarkers in Acute Coronary Syndromes: A Review
Current Vascular Pharmacology The Current Role of Statin Therapy in the Treatment of Atrial Fibrillation
Cardiovascular & Hematological Agents in Medicinal Chemistry Lesson from the Pandemic: People should Always Stay Physically Active
Current Cardiology Reviews Tuberculosis Treated by Multiple Drugs: An Overview
Current Drug Delivery Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations
Current Genomics